Asahi Kasei
VC Fund
Tokyo, Japan
Asahi Kasei is a VC fund in Tokyo focused on Health Care and Biotechnology. Asahi Kasei Corporation provides solutions based in chemistry and materials science to a range of markets, including fibers, chemicals, consumer products, housing, construction, electronics, and health care primarily in Japan. Segments Chemicals The Chemicals Segment offers organic and inorganic industrial chemicals, synthetic resin, syntheticrubber, high-compound fertilizer, coating materials, latex, pharmaceutical and food additives, explosives, photopolymers and platemaking systems, separation and ion-exchange membranes, systems, and equipment. The company produces, processes, and sells chemicals and derivative products, such as ammonia, nitric acid, caustic soda, acrylonitrile, styrene monomer, methyl methacrylate (MMA) monomer, PMMA resin, high-compound fertilizers, and adipic acid; polymer products, such as Suntec polyethylene (PE), Stylac-AS (styrene-acrylonitrile), Stylac-ABS (acrylonitrile-butadiene-styrene), synthetic rubber, Tenac polyacetal, Xyron modified polyphenylene ether (mPPE), and Leona nylon 66 polymer and filament); and specialty products, such as coating materials, latex, Ceolus microcrystalline cellulose, explosives, explosion-bonded metal clad, APR photosensitive resin and printing plate making systems, Microza UF and MF membranes and systems, Hipore microporous membrane, ion-exchange membranes and electrolysis systems, Saran Wrap cling film, Ziploc storage bags, and plastic films, sheets, and foams.
- Total investments:
- 41
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Asahi Kasei invests in
Stages Asahi Kasei invests in
Countries Asahi Kasei invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3.3M–$32M
- Series B
- $7.7M–$48M
- Series C
- $12M–$52M
Investment Focus
Industry
- Health Care 12 (29%)
- Biotechnology 12 (29%)
- Therapeutics 9 (22%)
- Medical 8 (20%)
- Manufacturing 7 (17%)
Stage
- Series C 10 (24%)
- Series B 9 (22%)
- Series A 7 (17%)
- Seed 6 (15%)
- Funding Round 4 (10%)
Country
- United States 20 (49%)
- Japan 5 (12%)
- Canada 4 (10%)
- Israel 4 (10%)
- France 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Hideki Kobori
CEO
|
CEO | Total investments: 0 | Find email | |
Takashi Morishita
General Manager
|
General Manager | Total investments: 4 | Find email | |
Kazuma Komatsu
Team Member
|
Team Member | Total investments: 0 | Find email | |
Masahiro Mori
Team Member
|
Team Member | Total investments: 0 | Find email | |
Shitagau Noguchi
Founder
|
Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
KEWAZO
|
KEWAZO is digitizing construction with robotics and data analytics. We integrate robotic platforms on-site to enable digital services. In scaffolding, our robotic material hoist LIFTBOT saves up to 44% of labor costs, addresses labor shortage, and improves safety. By having our robots on-site, we collect operational data and provide it to ourcustomers in the form of a data analytics platform, enabling more proactive management of both individual projects and companies overall. | $16M / Series A / Mar 19, 2026 | |
Mangrove Lithium
|
Mangrove Lithium, a Vancouver-based company, has developed a breakthrough platform for the most cost-effective production of battery-grade lithium hydroxide and carbonate from diverse input streams and assets. Mangrove’s modular solution can be scaled to any capacity and co-located with upstream lithium producers or cathode and cell manufacturers.The platform technology is also being commercialized for the conversion of waste brines to chemicals and desalinated water. | $35M / Jan 28, 2025 | |
Rege Nephro
|
Rege Nephro is a biotech company that specialized in R&D, production and marketing of renal disease therapeutics. | $15.2M / Series B / Oct 07, 2024 | |
24M Technologies
|
24M Technologies develops energy storage systems for grid and transportation applications. It offers binder-free semisolid electrodes and unit cells, eliminating the need for hydro or pyrometallurgical processes for battery recycling. It also helps direct in-plant reuse of active material for end-of-life recycling. | $87M / Series H / Sep 05, 2024 | |
Cyto-Facto
|
Cyto-Facto is a biotechnology company that develops and manufactures CAR-T cell therapies and mesenchymal stem cell products. | $7.6M / Series A / Apr 22, 2024 | |
Avation Medical
|
Avation Medical is pioneering new platforms for wearable nerve stimulation systems. They believe empowering patients to be in control of their therapies will allow for more personalized and custom care. That's why at Avation Medical, they are re‑imagining neuromodulation by developing patient‑centric solutions based on powerful, proven, smarttechnologies.Avation Medical transforms the neuromodulation market to elevate care for patients with chronic conditions. | $22M / Series C / Feb 01, 2024 | |
Noctrix Health
|
Noctrix Health is an early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness. | $40M / Series C / Jan 16, 2024 | |
|
LeadSound Technology
|
LeadSound Technology researches battery non-destructive testing and monitoring technology. | Seed / Jan 02, 2024 | |
Ionomr
|
Ionomr is pioneering and commercializing the world's most advanced ion-exchange materials. These provide an enabling platform for clean tech solutions after more than five decades of stagnation in available materials. Using our deep knowledge of scalable electrochemical systems, we enable more efficient systems that will lead to thedecarbonization of the planet for future generations. To date, electrochemical applications in the clean tech realm use materials that contain toxic fluorinated chemicals (PFCs). PFCs leach into water sources and bioaccumulate for hundreds of years, having a dire impact on human health and the entire ecosystem. We are driven to replace these materials with our environmentally friendly hydrocarbon alternatives that reduce pollution at the source, and are proven to be more durable and efficient than incumbent materials. Ionomr's membranes and polymers are highly processable, which allow for simple integration into electrochemical systems. We enable optimal performance in applications for chemical & water remediation, energy storage and hydrogen. We are passionate about empowering the development of resilient and sustainable systems that will underlie the future of the renewable energy and circular chemical economies. | $20M / Series A / Dec 05, 2023 | |
Ossium Health
|
Ossium is building the world's first bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation.The cells of the immune system are the human body’s natural defenders against disease. At Ossium, they are developing better methods of recovering, preserving, deploying these critical cells to keepdisease at bay. | $52M / Series C / Jul 25, 2023 | |
| See all 41 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Asahi Kasei invest in?
Asahi Kasei invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series C and Series B stage. Most of the 41 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Asahi Kasei's check size?
Asahi Kasei typically joins rounds of $3.3M–$32M at Series A, $7.7M–$48M at Series B and $12M–$52M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Asahi Kasei participates in.
How do I contact Asahi Kasei?
Public channels for Asahi Kasei include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Asahi Kasei?
The team at Asahi Kasei includes Hideki Kobori (CEO), Takashi Morishita (General Manager) and Kazuma Komatsu (Team Member). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
